<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PENNSAID- diclofenac sodium liquid </strong><br>Lake Erie Medical DBA Quality Care Products LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PENNSAID<span class="Sup">®</span> safely and effectively. See full prescribing information for PENNSAID.<br><br>

PENNSAID (diclofenac sodium topical solution) 1.5% w/w is for topical use only.
<br>
Initial U.S. Approval: 1988</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK<br><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<br><span class="Bold">Cardiovascular Risk<br></span><ul>
<li><span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#s51">5.1</a>)</span></li>
<li><span class="Bold">PENNSAID is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#s4">4</a>) </span></li>
</ul>
<span class="Bold">Gastrointestinal Risk</span><br><ul><li><span class="Bold">NSAIDs, including PENNSAID, cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (<a href="#s52">5.2</a>)</span></li></ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK<br><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<br><span class="Bold">Cardiovascular Risk<br></span><ul>
<li><span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#s51">5.1</a>)</span></li>
<li><span class="Bold">PENNSAID is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#s4">4</a>) </span></li>
</ul>
<span class="Bold">Gastrointestinal Risk</span><br><ul><li><span class="Bold">NSAIDs, including PENNSAID, cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (<a href="#s52">5.2</a>)</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">PENNSAID is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee(s). (<a href="#s1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee(s), the recommended dose is 40 drops on each painful knee, 4 times a day. (<a href="#s2">2</a>)</span><br> </p>
<ul>
<li>Apply PENNSAID to clean, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>. (<a href="#s21">2.1</a>)</li>
<li>Dispense PENNSAID 10 drops at a time either directly onto the knee or first into the hand and then onto the knee. Spread PENNSAID evenly around front, back and sides of the knee. Repeat this procedure until 40 drops have been applied and the knee is completely covered with solution. (<a href="#s21">2.1</a>)</li>
<li>Wash hands completely after administering the product.</li>
<li>Wait until the area is completely dry before covering with clothing or applying sunscreen, insect repellent, cosmetics, topical medications, or other substances.</li>
<li>Do not get PENNSAID in your eyes, nose or mouth.</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>1.5% w/w topical solution (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diclofenac sodium. (<a href="#s4">4</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. (<a href="#s4">4</a>)</li>
<li>Use in the perioperative period of coronary artery bypass graft (CABG) surgery. (<a href="#s4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Serious and potentially fatal cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> can occur with NSAID treatment. Use the lowest effective dose of PENNSAID in patients with known CV disease or risk factors for CV disease. (<a href="#s51">5.1</a>)</li>
<li>NSAIDs can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation. Prescribe PENNSAID with caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. (<a href="#s52">5.2</a>)</li>
<li>Elevation of one or more liver tests may occur during therapy with NSAIDs. Discontinue PENNSAID immediately if abnormal liver tests persist or worsen. (<a href="#s53">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> can occur with NSAID treatment. Monitor blood pressure closely with PENNSAID treatment. (<a href="#s54">5.4</a>)</li>
<li>Use PENNSAID with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#s55">5.5</a>)</li>
<li>Long-term administration of NSAIDs can result in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Use PENNSAID with caution in patients at greatest risk of this reaction, including the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, and those taking diuretics and ACE-inhibitors. (<a href="#s56">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> may occur in patients with the aspirin triad or in patients without prior exposure to PENNSAID. (<a href="#s57">5.7</a>)</li>
<li>NSAIDs can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. (<a href="#s58">5.8</a>)</li>
<li>Not for use during pregnancy. (<a href="#s59">5.9</a>)</li>
<li>Do not administer to patients with aspirin sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and use with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#s510">5.10</a>)</li>
<li>Avoid exposure of treated knee(s) to natural or artificial sunlight. (<a href="#s511">5.11</a>)</li>
<li>Avoid contact of PENNSAID with eyes and mucosa. (<a href="#s512">5.12</a>)</li>
<li>Avoid concurrent use with oral NSAIDs. (<a href="#s513">5.13</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common adverse events with PENNSAID are <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. (<a href="#s61">6.1</a>)<br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mallinckrodt Brand Pharmaceuticals, Inc. at 1-800-778-7898 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#s71">7.1</a>)</li>
<li>Concomitant use of anticoagulants and diclofenac have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone. (<a href="#s72">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Not recommended for use during pregnancy. (<a href="#s81">8.1</a>)</li>
<li>Nursing Mothers: Use with caution, as it is not known if diclofenac is excreted in human milk. (<a href="#s83">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK</a></h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Special Precautions</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Gastrointestinal Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Renal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Pregnancy</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Sun Exposure</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Eye Exposure</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Oral Nonsteroidal Anti-Inflammatory Drugs</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Hematological Effects</a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Monitoring</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Aspirin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Anticoagulants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 ACE-Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Diuretics</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Lithium</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Methotrexate</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Cyclosporine</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Oral Nonsteroidal Anti-Inflammatory Drugs</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Topical Treatments</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Platelets</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Pivotal Studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> of the Knee</a></h2>
<h1><a href="#section-14" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Patient/Caregiver Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Cardiovascular Effects</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Gastrointestinal Effects</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Hepatotoxicity</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-15.8" class="toc">17.8 Effects During Pregnancy</a></h2>
<h2><a href="#section-15.9" class="toc">17.9 Eye Exposure</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK</h1>
<p class="First"><span class="Bold">Cardiovascular Risk<br></span></p>
<ul>
<li><span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk <span class="Italics">[see <a href="#s51">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li><span class="Bold">PENNSAID is contraindicated in the perioperative setting of coronary artery bypass graft (CABG) surgery 
                  <span class="Italics">[see <a href="#s4">Contraindications (4)</a>]</span>.</span></li>
</ul>
<span class="Bold">Gastrointestinal Risk</span><br><ul><li><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events <span class="Italics">[<span class="Italics">see <a href="#s52">Warnings and Precautions (5.2)</a></span>]</span>.</span></li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<p class="First">PENNSAID is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee(s).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Instructions</h2>
<p class="First">For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee(s), the recommended dose is 40 drops per knee, 4 times a day.</p>
<p>Apply PENNSAID to clean, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>.</p>
<p>To avoid spillage, dispense PENNSAID 10 drops at a time either directly onto the knee or first into the hand and then onto the knee. Spread PENNSAID evenly around front, back and sides of the knee. Repeat this procedure until 40 drops have been applied and the knee is completely covered with solution.</p>
<p>To treat the other knee, if symptomatic, repeat the procedure.</p>
<p>Application of PENNSAID in an amount exceeding or less than the recommended dose has not been studied and is therefore not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Special Precautions</h2>
<ul>
<li>Avoid showering/bathing for at least 30 minutes after the application of PENNSAID to the treated knee.</li>
<li>Wash and dry hands after use.</li>
<li>Do not apply PENNSAID to open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</li>
<li>Avoid contact of PENNSAID with eyes and mucous membranes.</li>
<li>Do not apply external heat and/or occlusive dressings to treated knees.</li>
<li>Avoid wearing clothing over the PENNSAID-treated knee(s) until the treated knee is dry.</li>
<li>Protect the treated knee(s) from sunlight.</li>
<li>Wait until the treated area is dry before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same knee you have just treated with PENNSAID.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">1.5% w/w topical solution</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<p class="First">PENNSAID is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diclofenac sodium or any other component of PENNSAID.</p>
<p>PENNSAID is contraindicated in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients <span class="Italics">[<span class="Italics">see Warnings and Precautions (<a href="#s57">5.7</a>, <a href="#s510">5.10</a>)</span>]</span>.</p>
<p>PENNSAID is contraindicated in the setting of coronary artery bypass graft (CABG) surgery <span class="Italics">[<span class="Italics">see <a href="#s51">Warnings and Precautions (5.1)</a></span>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several oral COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, including PENNSAID and COX-2 selective and nonselective orally administered NSAIDs, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Inform patients about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>Two large, controlled, clinical trials of an orally administered COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see <a href="#s4">Contraindications (4)</a>]</span>.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.<br><br>The concurrent use of aspirin and NSAIDs, such as diclofenac, does increase the risk of serious GI events <span class="Italics">[see <a href="#s52">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Gastrointestinal Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First">NSAIDs, including diclofenac, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>Prescribe NSAIDs, including PENNSAID, with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, use special care when treating this population.</p>
<p>To minimize the potential risk for an adverse GI event, use the lowest effective dose for the shortest possible duration. Remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during diclofenac therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. For high-risk patients, consider alternate therapies that do not involve NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">Borderline elevations (less than 3 times the upper limit of the normal [ULN] range) or greater elevations of transaminases occurred in about 15% of oral diclofenac-treated patients in clinical trials of indications other than <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>. Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.</p>
<p>In clinical trials of an oral diclofenac-misoprostol combination product, meaningful elevations (i.e., more than 3 times the ULN) of AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment (ALT was not measured in all studies).</p>
<p>In an open-label, controlled trial of 3,700 patients treated for 2 to 6 months, patients with oral diclofenac were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of the 3,700 patients and included marked elevations (&gt;8 times the ULN) in about 1% of the 3,700 patients. In this open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (&gt;8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs. Elevations in transaminases were seen more frequently in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> than in those with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. Almost all meaningful elevations in transaminases were detected before patients became symptomatic.</p>
<p>Abnormal tests occurred during the first 2 months of therapy with oral diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations. In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of NSAID therapy.</p>
<p>Postmarketing surveillance has reported cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with and without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these reported cases resulted in fatalities or liver transplantation.</p>
<p>In a European retrospective population-based, case-controlled study, 10 cases of oral diclofenac associated drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with current use compared with non-use of diclofenac were associated with a statistically significant 4-fold adjusted odds ratio of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. In this particular study, based on an overall number of 10 cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> associated with diclofenac, the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more then 90 days.</p>
<p>Measure transaminases (ALT and AST) periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, monitor transaminases within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac. If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, dark urine, etc.), discontinue PENNSAID immediately.</p>
<p>To minimize the possibility that hepatic injury will become severe between transaminase measurements, inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flulike" symptoms), and the appropriate action to take if these signs and symptoms appear.</p>
<p>To minimize the potential risk for an adverse liver-related event in patients treated with PENNSAID, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing PENNSAID with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, certain antibiotics, antiepileptics). Caution patients to avoid taking unprescribed acetaminophen while using PENNSAID.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including diclofenac, can lead to new onset or worsening of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Use NSAIDs, including PENNSAID, with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure (BP) closely during the initiation of NSAID treatment and throughout the course of therapy. <br></p>
<p>Patients taking ACE-inhibitors, thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients treated with NSAIDs, including PENNSAID. Use PENNSAID with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Renal Effects</h2>
<p class="First">Use caution when initiating treatment with PENNSAID in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE-inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<p>No information is available from controlled clinical studies regarding the use of PENNSAID in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with PENNSAID is not recommended in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If PENNSAID therapy is initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without prior exposure to PENNSAID. Do not prescribe PENNSAID to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs <span class="Italics">[see <a href="#s4">Contraindications (4)</a> and <a href="#s510">Warnings and Precautions (5.10)</a>]</span>. Seek emergency help in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Do not apply PENNSAID to open skin <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>, or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, as it may affect absorption and tolerability of the drug.</p>
<p>NSAIDs, including PENNSAID, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin manifestations, and discontinue use of the drug at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s59"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Pregnancy</h2>
<p class="First">PENNSAID should not be used by pregnant or nursing women or those intending to become pregnant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s510"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross-reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, do not administer PENNSAID to patients with this form of aspirin sensitivity and use with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s511"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Sun Exposure</h2>
<p class="First">Instruct patients to avoid exposure to natural or artificial sunlight on treated knee(s) because studies in animals indicated topical diclofenac treatment resulted in an earlier onset of ultraviolet light-induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span>. The potential effects of PENNSAID on skin response to ultraviolet damage in humans are not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s512"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Eye Exposure</h2>
<p class="First">Avoid contact of PENNSAID with eyes and mucosa. Advise patients that if eye contact occurs, immediately wash out the eye with water or saline and consult a physician if irritation persists for more than an hour.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s513"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Oral Nonsteroidal Anti-Inflammatory Drugs</h2>
<p class="First">Concomitant use of oral NSAIDs with PENNSAID resulted in a higher rate of <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, more frequent abnormal creatinine, urea and hemoglobin. Therefore, do not use combination therapy with PENNSAID and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s514"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Corticosteroid Treatment</h2>
<p class="First">PENNSAID cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-response illness. For patients on prolonged corticosteroid therapy, taper slowly if a decision is made to discontinue corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s515"></a><a name="section-5.15"></a><p></p>
<h2>5.15 <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">The pharmacological activity of PENNSAID in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and possibly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s516"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Hematological Effects</h2>
<p class="First">The effects of PENNSAID on platelet function were studied in 10 healthy subjects administered 80 drops four times a day for 7 days. There was no significant change in platelet aggregation following one week of treatment <span class="Italics">[see <a href="#s124">Clinical Pharmacology (12.4)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Check hemoglobin or hematocrit of patients on PENNSAID if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration and reversible. Carefully monitor patients receiving PENNSAID who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s517"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Monitoring</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms in patients taking NSAIDs, monitor patients for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Check CBC and a chemistry profile periodically in patients on long-term treatment with NSAIDs. Discontinue PENNSAID if abnormal liver tests or renal tests persist or worsen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<br><div class="Section" data-sectionCode="34092-7">
<a name="s61"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to PENNSAID of 911 patients treated between 4 and 12 weeks (mean duration of 49 days) in seven Phase 3 controlled trials, as well as exposure of 793 patients treated in an open-label study, including 463 patients treated for at least 6 months, and 144 patients treated for at least 12 months. The population mean age was approximately 60 years, 89% of patients were Caucasians, 64% were females, and all patients had primary <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>. The most common adverse events with PENNSAID were application site <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. These events were the most common reason for withdrawing from the studies.</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span>:</span></p>
<p>In controlled trials, the most common treatment-related adverse events in patients receiving PENNSAID were application site <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> were characterized by one or more of the following: dryness, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. The most frequent of these reactions were <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> (32%), <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> characterized by <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> (9%), <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> (2%) and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (4%). In one controlled trial, a higher rate of <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> (4%) was observed after treatment of 152 subjects with the combination of PENNSAID and oral diclofenac. In the open label uncontrolled long-term safety study, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> occurred in 13% and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> in 10% of patients, generally within the first 6 months of exposure, leading to a withdrawal rate for an application site event of 14%.</p>
<p><span class="Italics Underline">Adverse events common to the NSAID class:</span></p>
<p>In controlled trials, subjects treated with PENNSAID experienced some adverse events associated with the NSAID class more frequently than subjects using placebo (<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; see <a href="#table1">Table 1</a>). The combination of PENNSAID and oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> (3% vs. less than 1%), and more frequent abnormal creatinine (12% vs. 7%), urea (20% vs. 12%), and hemoglobin (13% vs. 9%), but no difference in elevation of liver transaminases.</p>
<p>Table 1 lists all adverse reactions occurring in ≥1% of patients receiving PENNSAID, where the rate in the PENNSAID group exceeded placebo, from seven controlled studies conducted in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>. Since these trials were of different durations, these percentages do not capture cumulative rates of occurrence.</p>
<a name="table1"></a><table cellpadding="4" width="100%">
<caption><span>Table 1: Adverse Reactions occurring in ≥1% of patients treated with PENNSAID<span class="Sup">®</span> in placebo and oral diclofenac-controlled trials.</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">†</span>Preferred Term according to COSTART</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="right" valign="top"><span class="Bold">Treatment Group: </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PENNSAID<span class="Sup">®</span><br>N=911 </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Topical Placebo<br>N=332 </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Adverse Reaction<span class="Sup">† </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N (%) </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N (%) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span> (Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">292 (32) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">17 (5) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span> (Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">83 (9) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">72 (8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 (4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">54 (6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 (3) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">35 (4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (Application Site)  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">34 (4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">33 (4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">33 (4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 (4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 (4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">29 (3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">26 (3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (Non-Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">25 (3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">25 (3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">19 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span> (Non-Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">19 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> (Application Site)  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">18 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> (Non-Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">14 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">22 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (Non-Application Site) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 (2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 (1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (&lt;1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">Halitosis</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11 (1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;1) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span> (not otherwise specified) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11 (1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (&lt;1) </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In non-US postmarketing surveillance, the following adverse reactions have been reported during post-approval use of PENNSAID. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br><br><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">body odor</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, lack of drug effect, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorder</span></p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span><br></p>
<p><span class="Italics">Metabolic and Nutritional:</span> creatinine increased<br></p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span><br></p>
<p><span class="Italics">Nervous:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> at application site<br></p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span><br></p>
<p><span class="Italics">Skin and Appendages: At the Application Site:</span> <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Italics">Other Skin and Appendages Adverse Reactions:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><br></p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorder</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<p class="First">Drug interactions with the use of PENNSAID have not been studied. The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Aspirin</h2>
<p class="First">When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Anticoagulants</h2>
<p class="First">The effects of anticoagulants such as warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 ACE-Inhibitors</h2>
<p class="First">NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors. Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>7.4 Diuretics</h2>
<p class="First">Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. The response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe the patient closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> <span class="Italics">[see <a href="#s56">Warnings and Precautions (5.6)</a>]</span>, as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>7.5 Lithium</h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>7.6 Methotrexate</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>7.7 Cyclosporine</h2>
<p class="First">Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Therefore, concomitant therapy with diclofenac may increase cyclosporine’s <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Use caution when diclofenac is administered concomitantly with cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>7.8 Oral Nonsteroidal Anti-Inflammatory Drugs</h2>
<p class="First">Concomitant use of oral NSAIDs with PENNSAID has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span> (3% vs. less than 1%), and more frequent abnormal creatinine (12% vs. 7%), urea (20% vs. 12%) and hemoglobin (13% vs. 9%). Therefore, do not use combination therapy with PENNSAID and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9"></a><p></p>
<h2>7.9 Topical Treatments</h2>
<p class="First">Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with PENNSAID, they must wait until the treated area is completely dry.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<br><div class="Section" data-sectionCode="42228-7">
<a name="s81"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C prior to 30 weeks gestation; Category D starting 30 weeks gestation.<br><br><span class="Italics">Teratogenic Effects:</span><br></p>
<p>There are no adequate and well-controlled studies of PENNSAID in pregnant women. PENNSAID should not be used by pregnant women as its safe use has not been adequately determined and starting at 30 weeks gestation, diclofenac and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. Developmental studies in animals demonstrated that diclofenac sodium administration did not produce <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> despite the induction of maternal toxicity and fetal toxicity in mice at doses up to 20 mg/kg/day (0.6-fold the maximum recommended human dose [MRHD] of 154 mg/day based on body surface area comparison), and in rats and rabbits at doses up to 10 mg/kg/day (approximately 0.6-fold and 1.3-fold the MRHD, respectively). Published reproductive and developmental studies of dimethyl sulfoxide (DMSO, the solvent used in PENNSAID) are equivocal as to potential <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.<br></p>
<p><span class="Italics">Nonteratogenic Effects:</span></p>
<p>In rats, maternally toxic doses of diclofenac were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effects of PENNSAID on labor and delivery in pregnant women are unknown. In rat studies maternal exposure to diclofenac, as with other NSAID drugs, known to inhibit prostaglandin synthesis, increased the incidence of dystocia, delayed parturition, and decreased offspring survival.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s83"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk; however, there is a case report in the literature indicating that diclofenac can be detected at low levels in breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from PENNSAID, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 911 patients treated with PENNSAID in seven controlled, Phase 3 clinical trials, 444 subjects were 65 years of age and over. There was no age-related difference in the incidence of adverse events. Of the 793 patients treated with PENNSAID in one open-labeled safety trial, 334 subjects were 65 years of age and over including 107 subjects 75 and over. There was no difference in the incidence of adverse events with long-term exposure to PENNSAID for this elderly population. As with any NSAID, use caution in treating the elderly (65 years and older) and it may be useful to monitor renal function since they are more likely to have decreased baseline renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">There have been no known experiences of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with PENNSAID.<br></p>
<p>Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.<br></p>
<p>Manage patients using symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> is not recommended due to a possibility of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> and subsequent respiratory irritation by DMSO contained in PENNSAID. Activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.<br></p>
<p>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison control center (1-800-222-1222).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">PENNSAID is a clear, colorless to faintly pink-orange solution for topical application.</p>
<p>PENNSAID contains 1.5% w/w diclofenac sodium, a benzeneacetic acid derivative that is a nonsteroidal anti-inflammatory drug (NSAID), designated chemically as 2-[(2,6-dichlorophenyl)amino]-benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">10</span>Cl<span class="Sub">2</span>NNaO<span class="Sub">2</span> and it has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43d7d5d1-a593-4b97-ae24-f3e92be90004&amp;name=pennsaidchemstruc.jpg"></div>
<p>Each 1 mL of solution contains 16.05 mg of diclofenac sodium. In addition, PENNSAID contains the following inactive ingredients: dimethyl sulfoxide USP (DMSO, 45.5% w/w), propylene glycol, alcohol, glycerin and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<br><div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of diclofenac is similar to that of other nonsteroidal anti-inflammatory drugs. Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin. It is not completely understood how reduced synthesis of these compounds results in therapeutic efficacy.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Diclofenac, the active component of PENNSAID has anti-inflammatory, anti-nociception, and antipyretic effects.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s123"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">After topical administration to healthy human volunteers of single and multiple maximum doses of PENNSAID, 40 drops (approximately 1.2 mL) to each knee (80 drops total dose), the following diclofenac pharmacokinetic parameters were obtained: (see <a href="#table2">Table 2</a>).</p>
<a name="table2"></a><table cellpadding="4" width="100%">
<caption><span>Table 2: Single-Dose (80 drops) and Multiple Dose (80 drops four times daily for 7 days) PENNSAID Pharmacokinetic Parameters</span></caption>
<col align="left" width="30%">
<col align="center" width="35%">
<col align="center" width="35%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span>Apparent total body clearance</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3"><span class="Bold">Pharmacokinetic Parameters</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Diclofenac sodium</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Normal Adults [N=18]<br>(Age: 18-55 years)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Normal Adults [N=19]<br>(Age: 18-55 years)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Single Dose</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Multiple Dose</span><br>Four times daily for 7 days </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">AUC<span class="Sub">0-t</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">177.5 ± 72.6 ng.h/mL </td>
<td class="Botrule Lrule Rrule Toprule" align="center">695.4 ± 348.9 ng.h/mL </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">AUC<span class="Sub">0-inf</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">196.3 ± 68.5 ng.h/mL </td>
<td class="Botrule Lrule Rrule Toprule" align="center">745.2 ± 374.7 ng.h/mL </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Plasma C<span class="Sub">max</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.1 ± 5.9 ng/mL </td>
<td class="Botrule Lrule Rrule Toprule" align="center">19.4 ± 9.3 ng/mL </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Plasma T<span class="Sub">max</span> (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11.0 ± 6.4 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.0 ± 6.5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Plasma t<span class="Sub">1/2</span> (h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">36.7 ± 20.8 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">79.0 ± 38.1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Kel (h<span class="Sup">-1</span>) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.024 ± 0.010 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.011 ± 0.004 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">CL/F (L/h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">244.7 ± 84.7<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">--</td>
</tr>
</tbody>
</table>
<p>Absorption<br><br>Diclofenac systemic exposure from PENNSAID application (4 times daily for 1 week) was approximately 1/3 of the diclofenac systemic exposure from the Solaraze (diclofenac topical gel) application (twice daily for 4 weeks).<br><br>Distribution<br><br>Diclofenac is more than 99% bound to human serum proteins, primarily to albumin.<br><br>Diclofenac diffuses into and out of the synovial fluid. Diffusion into the joint occurs when plasma levels are higher than those in the synovial fluid, after which the process reverses and synovial fluid levels are higher than plasma levels. It is not known whether diffusion into the joint plays a role in the effectiveness of diclofenac.<br><br>Metabolism<br><br>Five diclofenac metabolites have been identified in human plasma and urine. The metabolites include 4'-hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy diclofenac. The major diclofenac metabolite, 4'-hydroxy-diclofenac, has very weak pharmacologic activity. The formation of 4'-hydroxy diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuronidation mediated by UGT2B7 and oxidation mediated by CPY2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3'-hydroxy-diclofenac.<br><br>Excretion<br><br>Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.<br><br>Little or no free unchanged diclofenac is excreted in the urine.<br><br>Special Populations<br><br><span class="Italics">Pediatric: </span>The pharmacokinetics of PENNSAID has not been investigated in pediatric patients.<br><br><span class="Italics">Race:</span> Pharmacokinetic differences due to race have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s124"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Platelets</h2>
<p class="First">The effect of PENNSAID on platelet function was evaluated in 10 healthy human volunteers as a sub-study of a multiple-dose pharmacokinetic study <span class="Italics">[see <a href="#s123">Pharmacokinetics (12.3)</a>]</span>. Average (range) platelet aggregation time following stimulation with adenosine diphosphate, collagen, epinephrine and arachidonic acid was 101.3% (73.3 to 128.1), 99.8% (69.6 to 112.9), 109.9% (66.2 to 178.1) and 99.0% (15.5 to 126.6) of baseline value, respectively. These results indicate that there was no effect on platelet aggregation after application of the maximum clinical dose for 7 days <span class="Italics">[see <a href="#s123">Pharmacokinetics (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<br><div class="Section" data-sectionCode="34083-6">
<a name="s131"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies in mice and rats administered diclofenac sodium as a dietary constituent for 2 years resulted in no significant increases in tumor incidence at doses up to 2 mg/kg/day corresponding to approximately 0.35- and 0.7-fold (mouse and rat, respectively) of the maximum recommended human topical dose (MRHD) of PENNSAID (based on apparent bioavailability and body surface area comparison).<br></p>
<p>In a dermal carcinogenicity study conducted in albino mice, daily topical applications of diclofenac sodium for two years at concentrations up to 0.035% diclofenac sodium (a 43-fold lower diclofenac sodium concentration than present in PENNSAID) did not increase neoplasm incidence.<br></p>
<p>In a photococarcinogenicity study conducted in hairless mice, topical application of diclofenac sodium at doses up to 0.035% diclofenac sodium (a 43-fold lower diclofenac sodium concentration than present in PENNSAID) resulted in an earlier median time of onset of tumors.<br></p>
<p>Mutagenesis: Diclofenac was not mutagenic or clastogenic in a battery of genotoxicity tests that included the bacterial reverse mutation assay, in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> point mutation assay, chromosomal aberration studies in Chinese hamster ovarian cells in vitro, and in vivo rat chromosomal aberration assay of bone marrow cells.<br></p>
<p>Impairment of Fertility: Fertility studies have not been conducted with PENNSAID. Diclofenac sodium administered to male and female rats at doses up to 4 mg/kg/day (1.4-fold of the MRHD of PENNSAID based on apparent bioavailability and body surface area comparison) did not affect fertility. Studies have not been conducted to determine the safety of DMSO on fertility.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Ocular Effects</p>
<p>No adverse effects were observed using indirect ophthalmoscopy after multiple-daily dermal application to rats for 26 weeks and minipigs for 52 weeks of DMSO at twice the concentration found in PENNSAID. Published studies of dermal or oral administration of DMSO to rabbits, dogs and pigs described refractive changes of lens curvature and cortical fibers indicative of myopic changes and/or incidences of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span> or discoloration when evaluated using slit-lamp biomicroscopy examination, although no ocular abnormalities were observed in rhesus monkeys during daily oral or dermal treatment with DMSO for 9 to 18 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Pivotal Studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> of the Knee</h2>
<p class="First">The use of PENNSAID for the treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee was evaluated in two double-blind controlled trials conducted in the US and Canada, involving patients treated with PENNSAID at a dose of 40 drops four times a day for 12 weeks. PENNSAID was compared to topical placebo (2.3% DMSO with other excipients) and/or topical vehicle solution (45.5% w/w DMSO with other excipients), applied directly to the study knee. In both trials, PENNSAID treatment resulted in statistically significant clinical improvement compared to placebo and/or vehicle, in all three primary efficacy variables―<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, physical function (Western Ontario and McMaster Universities LK3.1 OA Index (WOMAC) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and physical function dimensions) and Patient Overall Health Assessment (POHA)/Patient Global Assessment (PGA). Numerical results are summarized in Tables 3 and 4.</p>
<table cellpadding="4" width="100%">
<caption><span>Table 3: Change in treatment outcomes after 12 weeks of treatment in one study of efficacy of PENNSAID<span class="Sup">®</span></span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">1</span>placebo formulation included 2.3% DMSO<br><span class="Sup">2</span>vehicle formulation included 45.5% DMSO </p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Efficacy Variable</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><span class="Bold">Study I<br>Mean baseline score and mean change in efficacy variables after 12 weeks of treatment</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Mean Baseline score</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">PENNSAID<span class="Sup">®</span><br>N=154</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Topical placebo<span class="Sup">1</span><br>N=155</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Topical vehicle<span class="Sup">2</span><br>N=161</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">WOMAC <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score (Likert 3.1, 0–20) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-6.0 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-4.7 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-4.7 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">WOMAC physical function (Likert 3.1, 0–68) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">42 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-15.7 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-12.3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-12.1 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">POHA (0–4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.0 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.4 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-0.6 </td>
</tr>
</tbody>
</table>
<table cellpadding="4" width="100%">
<caption><span>Table 4: Change in treatment outcomes after 12 weeks of treatment in one study of efficacy of PENNSAID</span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">1</span>vehicle formulation included 45.5% DMSO</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Efficacy Variable</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Study II<br>Mean baseline score and mean change in efficacy variables after 12 weeks of treatment</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Mean Baseline score</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PENNSAID<br>N=164</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Topical vehicle<span class="Sup">1</span><br>N=162</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">WOMAC <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score (Likert 3.1, 0–20) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-5.9 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-4.4 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">WOMAC physical function (Likert 3.1, 0–68) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">42 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-15.3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-10.3 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">PGA (0–4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.1 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-1.0 </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PENNSAID is supplied as a clear, colorless to faintly pink-orange

solution containing 16.05 mg of diclofenac sodium per mL of solution,

in a white high density polyethylene bottle with a white low-density dropper

cap.</p>
<br><p><span class="Bold">NDC Number &amp; Size</span></p>
<table width="50%"><tbody class="Headless">
<tr class="First">
<td>15 mL bottle (physician sample)</td>
<td>NDC # 23635-310-11</td>
</tr>
<tr class="Last">
<td>150 mL bottle</td>
<td>NDC # 23635-310-15</td>
</tr>
</tbody></table>
<p><span class="Bold">Storage</span><br><br>

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP

Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See <a href="#s1710">FDA-Approved Medication Guide (17.10)</a> for specific patient instructions.</span></p>
<div class="Section" data-sectionCode="50744-2">
<a name="section-15.1"></a><p></p>
<h2>17.1 Patient/Caregiver Instructions</h2>
<p class="First">Inform patients of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Encourage patients to read the NSAID Medication Guide that accompanies each prescription dispensed prior to using PENNSAID <span class="Italics">[see <a href="#s1710">Medication Guide (17.10)</a> and <a href="#s1711">Patient Instructions for Use (17.11)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Cardiovascular Effects</h2>
<p class="First">PENNSAID, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and to ask for medical advice when observing any indicative sign or symptoms. Inform patients of the importance of this follow-up <span class="Italics">[see <a href="#s51">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>17.3 Gastrointestinal Effects</h2>
<p class="First">PENNSAID, like other NSAIDs, may cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, inform patients to be alert for the signs and symptoms of ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Instruct patients of the importance of this follow-up <span class="Italics">[see <a href="#s52">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<h2>17.4 Hepatotoxicity</h2>
<p class="First">Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flu-like? symptoms). If these occur, instruct patients to stop therapy with PENNSAID and seek immediate medical therapy <span class="Italics">[see <a href="#s53">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<h2>17.5 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">PENNSAID, like other NSAIDs, can cause serious systemic skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious systemic <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, instruct patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and to ask for medical advice when observing any indicative signs or symptoms <span class="Italics">[see <a href="#s58">Warnings and Precautions (5.8)</a>]</span>.</p>
<p>Advise patients to stop PENNSAID immediately if they develop any type of generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</p>
<p>PENNSAID can cause a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">localized skin reaction</span> at the application site. Advise patients to contact their physicians as soon as possible if they develop any type of localized <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site rash</span>.</p>
<p>Instruct patients not to apply PENNSAID to open skin <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>, or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, as it may affect absorption and reduce tolerability of the drug.</p>
<p>Instruct patients to wait until the area treated with PENNSAID is completely dry before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication.</p>
<p>Instruct patients to minimize or avoid exposure of treated knee(s) to natural or artificial sunlight.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Instruct patients to promptly report to their physician signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> following treatment with PENNSAID <span class="Italics">[see <a href="#s55">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">Inform patients of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, instruct patients to seek immediate emergency help <span class="Italics">[see <a href="#s57">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.8"></a><p></p>
<h2>17.8 Effects During Pregnancy</h2>
<p class="First">Instruct patients who are pregnant or intending to become pregnant not to use PENNSAID <span class="Italics">[see <a href="#s81">Use in Specific Populations (8.1)</a> and <a href="#s131">Impairment of Fertility (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.9"></a><p></p>
<h2>17.9 Eye Exposure</h2>
<p class="First">Instruct patients to avoid contact of PENNSAID with the eyes and mucosa. Advise patients that if eye contact occurs, immediately wash out the eye with water or saline and consult a physician if irritation persists for more than an hour.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s1710"></a><a name="section-16"></a><p></p>
<h1>17.10 Medication Guide</h1>
<p class="First"><span class="Bold Underline">Medication Guide For Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<p><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<br><br><p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span><br>This chance increases:</p>
<ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).?</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul>
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<ul>
<li>taking medicines called “corticosteroids? and “anticoagulants?</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug
(NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table cellpadding="4" width="100%">
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold">Serious side effects include:</span><ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Other side effects include:</span><ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul>
<p>
These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.</p>
<p>
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):</span></p>
<ul>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Bold Underline">NSAID medicines that need a prescription</span></p>
<table cellpadding="4" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" width="50%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">*Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAID, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Generic Name</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Tradename</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Celecoxib</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Celebrex<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Diclofenac</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Flector, Cataflam<span class="Sup">®</span>, Voltaren<span class="Sup">®</span>, Arthrotec™ (combined with misoprostol), PENNSAID<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Diflunisal</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Dolobid<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Etodolac</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Lodine<span class="Sup">®</span>, Lodine<span class="Sup">®</span>XL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Fenoprofen</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Nalfon<span class="Sup">®</span>, Nalfon<span class="Sup">®</span>200</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Flurbirofen</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Ansaid<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Ibuprofen</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Motrin<span class="Sup">®</span>, Tab- Profen<span class="Sup">®</span>, Vicoprofen<span class="Sup">®</span>* (combined with hydrocodone), Combunox™ (combined with oxycodone)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Indomethacin</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Indocin<span class="Sup">®</span>, Indocin<span class="Sup">®</span>SR, Indo-Lemmon™, Indomethagan™</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Ketoprofen</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Oruvail<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Ketorolac</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Toradol<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Mefenamic Acid</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Ponstel<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Meloxicam</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Mobic<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Nabumetone</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Relafen<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Naproxen</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Naprosyn<span class="Sup">®</span>, Anaprox<span class="Sup">®</span>, Anaprox<span class="Sup">®</span>DS, EC-Naproxyn<span class="Sup">®</span>, Naprelan<span class="Sup">®</span>, Naprapac<span class="Sup">®</span> (copackaged with lansoprazole)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Oxaprozin</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Daypro<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Piroxicam</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Feldene<span class="Sup">®</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Sulindac</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Clinoril<span class="Sup">®</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Tolmetin</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Tolectin<span class="Sup">®</span>, Tolectin DS<span class="Sup">®</span>, Tolectin<span class="Sup">®</span>600</td>
</tr>
</tbody>
</table>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1711"></a><a name="section-17"></a><p></p>
<h1>17.11 Patient Instructions for Use</h1>
<p class="First"><span class="Bold">Patient Instructions for Use<br>PENNSAID [pen/sed]<br>(diclofenac sodium topical solution)</span></p>
<p>Your doctor has prescribed PENNSAID<span class="Sup">®</span> to treat your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> in your knee(s) and help you manage your daily activities better.</p>
<p><span class="Bold">Before you use PENNSAID<span class="Sup">®</span>:</span></p>
<ul>
<li>Apply PENNSAID<span class="Sup">®</span> exactly as your doctor tells you. Do not apply PENNSAID<span class="Sup">®</span> anywhere on your body other than where your doctor tells you.</li>
<li>Apply PENNSAID<span class="Sup">®</span> on clean, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> that does not have any cuts, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>.</li>
<li>Use PENNSAID<span class="Sup">®</span> 4 times each day on your knee(s).</li>
<li>Do not get PENNSAID<span class="Sup">®</span> in your eyes, nose or mouth. Only use PENNSAID<span class="Sup">®</span> on your skin (topical use). If you get PENNSAID<span class="Sup">®</span> in your eyes, rinse your eyes right away with water or saline. Call your doctor if your eyes are irritated for more than one hour.</li>
</ul>
<p><span class="Bold">Steps for using PENNSAID<span class="Sup">®</span>:</span></p>
<p>Step 1. Wash your hands with soap and water before and after applying PENNSAID<span class="Sup">®</span>.<br><br> Step 2. Your total dose for each knee is 40 drops of PENNSAID<span class="Sup">®</span>. You will use 10 drops at a time. Put 10 drops of PENNSAID<span class="Sup">®</span><span class="Bold"> either</span> on your hand <span class="Bold">or</span> directly on your knee.<br><img alt="Dispensing drops" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43d7d5d1-a593-4b97-ae24-f3e92be90004&amp;name=figure1.jpg"><br><br><span class="Bold">Figure 1. Dispense 10 drops of PENNSAID<span class="Sup">®</span> at a time</span><br><br></p>
<p>Step 3. Spread PENNSAID<span class="Sup">®</span> evenly on the front, back and sides of your knee. Repeat this step 4 times so that your knee is completely covered with a <span class="Bold">total</span> of 40 drops of PENNSAID<span class="Sup">®</span>.<br><br><img alt="Spreading on front and side of knee" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43d7d5d1-a593-4b97-ae24-f3e92be90004&amp;name=figure2.jpg"></p>
<p><br><span class="Bold">Figure 2. Spread PENNSAID<span class="Sup">®</span> evenly on the front, and sides of your knee</span><br><br><img alt="Spreading on back of knee" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43d7d5d1-a593-4b97-ae24-f3e92be90004&amp;name=figure3.jpg"><br><br><span class="Bold">Figure 3. Spread PENNSAID<span class="Sup">®</span> evenly on the back of your knee</span><br><br></p>
<p>Step 4. Repeat steps 2 and 3 for the other knee if needed.</p>
<p><br></p>
<p><span class="Bold">After you use PENNSAID<span class="Sup">®</span>:<br>Do not</span></p>
<ul>
<li>cover your knee with clothing until your knee is completely dry</li>
<li>put sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medicines on your knee until it is completely dry</li>
<li>take a shower or a bath for at least 30 minutes after you put PENNSAID<span class="Sup">®</span> on your knee(s)</li>
<li>use heating pads or apply bandages to the skin where you have applied PENNSAID<span class="Sup">®</span>
</li>
<li>expose your skin to sunlight or artificial light (tanning booths) where you have put PENNSAID<span class="Sup">®</span>
</li>
</ul>
<p><span class="Bold">How should I store PENNSAID<span class="Sup">®</span>?</span></p>
<ul><li>Store PENNSAID<span class="Sup">®</span> between 59°F to 86°F (15°C to 30°C).</li></ul>
<p>Keep PENNSAID<span class="Sup">®</span> and all medicines out of the reach of children.</p>
<p><br></p>
<p>COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and/or internationally registered trademarks of Covidien AG. PENNSAID is a trademark of Nuvo Research Inc. Other brands are trademarks of their respective owners.</p>
<p><br></p>
<p>Distributed by:<br> Mallinckrodt Brand Pharmaceuticals, Inc.<br> Hazelwood, MO 63042 USA</p>
<p>Manufactured by:<br> Nuvo Manufacturing<br> Varennes, Quebec, J3X 1P7 Canada<br><br>Issued 01/2010<br><br>E0073-01<br><br><span class="Bold">Mallinckrodt<br><br>COVIDIEN™</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Lfa5fedc4-51fb-405e-914c-3eeb9bcef1f9"></a><a name="section-18"></a><p></p>
<h1>Image of Label</h1>
<p class="First"><img alt="Image of Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43d7d5d1-a593-4b97-ae24-f3e92be90004&amp;name=PennsaidTopical%20Solution.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PENNSAID 		
					</strong><br><span class="contentTableReg">diclofenac sodium liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:35356-590(NDC:23635-310)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DICLOFENAC SODIUM</strong> (DICLOFENAC) </td>
<td class="formItem">DICLOFENAC SODIUM</td>
<td class="formItem">16.05 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYL SULFOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:35356-590-15</td>
<td class="formItem">150 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020947</td>
<td class="formItem">04/05/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lake Erie Medical DBA Quality Care Products LLC
							(831276758)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lake Erie Medical DBA Quality Care Products LLC</td>
<td class="formItem"></td>
<td class="formItem">831276758</td>
<td class="formItem">relabel(35356-590)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3406f8c9-f2e8-4076-9016-15ed06f3b3dd</div>
<div>Set id: 43d7d5d1-a593-4b97-ae24-f3e92be90004</div>
<div>Version: 1</div>
<div>Effective Time: 20121115</div>
</div>
</div> <div class="DistributorName">Lake Erie Medical DBA Quality Care Products LLC</div></p>
</body></html>
